Trevi Therapeutics, Inc. (TRVI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$13.99+0.94%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · TRVI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -44.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
TRVI — earnings in line
Dated 2026-08-06
of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: The next report can show whether OCEAN-2 started and whether LAKE remains on plan. Delays would slow key trial work.
Watch forOn November 12, Trevi confirms OCEAN-2 started in Q3 and LAKE remains on track for its Q4 review.
Also watch forOn November 12, Trevi reports OCEAN-2 missed Q3 or the LAKE review moved past Q4.
Why it matters: OCEAN-2 is the second Phase 3 test of Haduvio for IPF cough. A timely start keeps both trials moving.
Supportive ifTrevi reports that OCEAN-2 began by September 30, 2026.
Worry ifTrevi reports that OCEAN-2 has not started by September 30, 2026, or gives a later start date.
Why it matters: The review will show whether LAKE can test Haduvio as planned or needs more patients. That can affect the trial's size and timing.
Watch forTrevi reports the review is complete and keeps the planned trial size and second-half 2027 data window.
Also watch forTrevi reports that the review calls for more patients or delays the planned second-half 2027 data window.
Why it matters: FDA feedback will shape the next trial in this second cough group. Clear agreement would support the planned study path.
Supportive ifTrevi reports FDA agreement on the trial plan and key steps needed to support a future filing.
Worry ifTrevi says FDA feedback calls for a major plan change or leaves key filing steps open.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$170 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $523 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,908 loss on $10,000 · 39.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.